An epigenetic approach to pancreatic cancer treatment: The prospective role of histone deacetylase inhibitors

Current Cancer Drug Targets

Volumn 12, Issue 4, 2012, Pages 439-452

  Tinari, Nicola ^a   de Tursi, Michele ^a   Grassadonia, Antonino ^a   Zilli, Marinella ^a   Stuppia, Liborio ^a   Iacobelli, Stefano ^a   Natoli, Clara ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cancer therapy; Epigenetic; Histone deacetylase; Histone deacetylase inhibitor; Molecular targeted therapy; Pancreatic ductal adenocarcinoma

Indexed keywords

BELINOSTAT; BORTEZOMIB; CAPECITABINE; DEPSIPEPTIDE; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; MOCETINOSTAT; PANOBINOSTAT; PEGINTERFERON ALPHA2B; PROTEASOME INHIBITOR; RESMINOSTAT; ROMIDEPSIN; SALINOSPORAMIDE A; TACEDINALINE; VALPROIC ACID; VORINOSTAT;

ABDOMINAL PAIN; ACETYLATION; ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL CYCLE ARREST; CHEMORESISTANCE; CUTANEOUS T CELL LYMPHOMA; DISEASE ASSOCIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TREATMENT FAILURE; EPIGENETICS; FATIGUE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC REGULATION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MEDICAL PARAMETERS; METASTASIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PLEIOTROPY; PROGNOSIS; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR XENOGRAFT; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE CHECKPOINTS; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84860283904     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800190884     Document Type: Article

References (163)

1. Vincent, A.; Herman, J.; Schulick, R.; Hruban, R. H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378 (9791), 607-620.
2. Burris, H. A., 3rd; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.;Stephens, C. D.; Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15 (6), 2403-2413.
3. Hu, J.; Zhao, G.; Wang, H. X.; Tang, L.; Xu, Y. C.; Ma, Y.; Zhang, F. C. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J. Hematol. Oncol. 2011, 4, 11.
4. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25 (15), 1960-1966.
5. Kindler, H. L.; Niedzwiecki, D.; Hollis, D.; Sutherland, S.; Schrag, D.; Hurwitz, H.; Innocenti, F.; Mulcahy, M. F.; O'Reilly, E.; Wozniak, T. F.; Picus, J.; Bhargava, P.; Mayer, R. J.; Schilsky, R. L.; Goldberg, R. M. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 2010, 28 (22), 3617-3622.
6. Philip, P. A.; Benedetti, J.; Corless, C. L.; Wong, R.; O'Reilly, E. M.; Flynn, P. J.; Rowland, K. M.; Atkins, J. N.; Mirtsching, B. C.; Rivkin, S. E.; Khorana, A. A.; Goldman, B.; Fenoglio-Preiser, C. M.; Abbruzzese, J. L.; Blanke, C. D. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Groupdirected intergroup trial S0205. J. Clin. Oncol. 2010, 28 (22), 3605-3610.
7. Conroy, T.; Desseigne, F.; Ychou, M.; Bouche, O.; Guimbaud, R.; Becouarn, Y.; Adenis, A.; Raoul, J. L.; Gourgou-Bourgade, S.; de la Fouchardiere, C.; Bennouna, J.; Bachet, J. B.; Khemissa-Akouz, F.; Pere-Verge, D.; Delbaldo, C.; Assenat, E.; Chauffert, B.; Michel, P.; Montoto-Grillot, C.; Ducreux, M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364 (19), 1817-1825.
8. Ko, A. H. FOLFIRINOX: A Small Step or a Great Leap Forward? J. Clin. Oncol. 2011.
9. Shi, S.; Yao, W.; Xu, J.; Long, J.; Liu, C.; Yu, X. Combinational therapy: New hope for pancreatic cancer? Cancer Lett. 2011.
10. Van Cutsem, E.; Aerts, R.; Haustermans, K.; Topal, B.; Van Steenbergen, W.; Verslype, C. Systemic treatment of pancreatic cancer. Eur. J. Gastroenterol. Hepatol. 2004, 16 (3), 265-274.
11. Neesse, A.; Gress, T. M.; Michl, P. Therapeutic targeting of apoptotic pathways: novel aspects in pancreatic cancer. Curr. Pharm. Biotechnol. 2011.
12. Zavoral, M.; Minarikova, P.; Zavada, F.; Salek, C.; Minarik, M. Molecular biology of pancreatic cancer. World J. Gastroenterol. 2011, 17 (24), 2897-2908.
13. Morris, J. P. t.; Wang, S. C.; Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 2010, 10 (10), 683-695.
14. Wang, J.; Sen, S. MicroRNA functional network in pancreatic cancer: from biology to biomarkers of disease. J. Biosci. 2011, 36 (3), 481-491.
15. Jones, S.; Zhang, X.; Parsons, D. W.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S. M.; Fu, B.; Lin, M. T.; Calhoun, E. S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D. R.; Hidalgo, M.; Leach, S. D.; Klein, A. P.; Jaffee, E. M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J. R.; Kern, S. E.; Hruban, R. H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321 (5897), 1801-1806.
16. Omura, N.; Goggins, M. Epigenetics and epigenetic alterations in pancreatic cancer. Int. J. Clin. Exp. Pathol. 2009, 2 (4), 310-326.
17. Bird, A. Perceptions of epigenetics. Nature 2007, 447 (7143), 396-398.
18. Jones, P. A.; Baylin, S. B. The epigenomics of cancer. Cell 2007, 128 (4), 683-692.
19. Glozak, M. A.; Seto, E. Histone deacetylases and cancer. Oncogene 2007, 26 (37), 5420-5432.
20. Monneret, C. Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs 2007, 18 (4), 363-370.
21. Khorasanizadeh, S. The nucleosome: from genomic organization to genomic regulation. Cell 2004, 116 (2), 259-272.
22. Narlikar, G. J.; Fan, H. Y.; Kingston, R. E. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002, 108 (4), 475-487.
23. Thiagalingam, S.; Cheng, K. H.; Lee, H. J.; Mineva, N.; Thiagalingam, A.; Ponte, J. F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. N. Y. Acad. Sci. 2003, 983, 84-100.
24. di Marcotullio, L.; Canettieri, G.; Infante, P.; Greco, A.; Gulino, A. Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim. Biophys. Acta 2011, 1815 (2), 241-252.
25. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363, 15-23.
26. Yao, Y. L.; Yang, W. M. Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates. J. Biomed. Biotechnol. 2011, 2011, 146493.
27. Ito, A.; Kawaguchi, Y.; Lai, C. H.; Kovacs, J. J.; Higashimoto, Y.; Appella, E.; Yao, T. P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002, 21 (22), 6236-6245.
28. Jin, Y. H.; Jeon, E. J.; Li, Q. L.; Lee, Y. H.; Choi, J. K.; Kim, W. J.; Lee, K. Y.; Bae, S. C. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J. Biol. Chem. 2004, 279 (28), 29409-29417.
29. Kotian, S.; Liyanarachchi, S.; Zelent, A.; Parvin, J. D. Histone deacetylases 9 and 10 are required for homologous recombination. J. Biol. Chem. 2011, 286 (10), 7722-7726.
30. Miller, K. M.; Tjeertes, J. V.; Coates, J.; Legube, G.; Polo, S. E.; Britton, S.; Jackson, S. P. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous endjoining. Nat. Struct. Mol. Biol. 2010, 17 (9), 1144-1151.
31. Uematsu, N.; Weterings, E.; Yano, K.; Morotomi-Yano, K.; Jakob, B.; Taucher-Scholz, G.; Mari, P. O.; van Gent, D. C.; Chen, B. P.; Chen, D. J. Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks. J. Cell. Biol. 2007, 177 (2), 219-229.
32. Yu, J.; Palmer, C.; Alenghat, T.; Li, Y.; Kao, G.; Lazar, M. A. The corepressor silencing mediator for retinoid and thyroid hormone receptor facilitates cellular recovery from DNA double-strand breaks. Cancer Res. 2006, 66 (18), 9316-9322.
33. Bhaskara, S.; Knutson, S. K.; Jiang, G.; Chandrasekharan, M. B.; Wilson, A. J.; Zheng, S.; Yenamandra, A.; Locke, K.; Yuan, J. L.; Bonine-Summers, A. R.; Wells, C. E.; Kaiser, J. F.; Washington, M. K.; Zhao, Z.; Wagner, F. F.; Sun, Z. W.; Xia, F.; Holson, E. B.; Khabele, D.; Hiebert, S. W. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 2010, 18 (5), 436-447.
34. Adimoolam, S.; Sirisawad, M.; Chen, J.; Thiemann, P.; Ford, J. M.; Buggy, J. J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (49), 19482-19487.
35. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27 (32), 5459-5468.
36. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370 (Pt 3), 737-749.
37. Blander, G.; Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73, 417-435.
38. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10 (1), 32-42.
39. Razidlo, D. F.; Whitney, T. J.; Casper, M. E.; McGee-Lawrence, M. E.; Stensgard, B. A.; Li, X.; Secreto, F. J.; Knutson, S. K.; Hiebert, S. W.; Westendorf, J. J. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One 2010, 5 (7), e11492.
40. Bhaskara, S.; Chyla, B. J.; Amann, J. M.; Knutson, S. K.; Cortez, D.; Sun, Z. W.; Hiebert, S. W. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol. Cell 2008, 30 (1), 61-72.
41. Verdin, E.; Dequiedt, F.; Kasler, H. G. Class II histone deacetylases: versatile regulators. Trends Genet. 2003, 19 (5), 286-293.
42. Gray, S. G.; Ekstrom, T. J. The human histone deacetylase family. Exp. Cell Res. 2001, 262 (2), 75-83.
43. Imai, S.; Guarente, L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol. Sci. 2010, 31 (5), 212-220.
44. Frye, R. A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 2000, 273 (2), 793-798.
45. Alhazzazi, T. Y.; Kamarajan, P.; Verdin, E.; Kapila, Y. L. SIRT3 and cancer: tumor promoter or suppressor? Biochim. Biophys. Acta 2011, 1816 (1), 80-88.
46. Haigis, M. C.; Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 2010, 5, 253-295.
47. Weichert, W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009, 280 (2), 168-176.
48. Blackwell, L.; Norris, J.; Suto, C. M.; Janzen, W. P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci. 2008, 82 (21/22), 1050-1058.
49. Federico, M.; Bagella, L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J. Biomed. Biotechnol. 2011, 2011, 475641.
50. Ouaissi, M.; Giger, U.; Sielezneff, I.; Pirro, N.; Sastre, B.; Ouaissi, A. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J. Biomed. Biotechnol. 2011, 2011, 315939.
51. Glaser, K. B. HDAC inhibitors: clinical update and mechanismbased potential. Biochem. Pharmacol. 2007, 74 (5), 659-671.
52. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5 (9), 769-784.
53. Richon, V. M.; Sandhoff, T. W.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97 (18), 10014-10019.
54. Shakespear, M. R.; Halili, M. A.; Irvine, K. M.; Fairlie, D. P.; Sweet, M. J. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011, 32 (7), 335-343.
55. Soragni, E.; Xu, C.; Cooper, A.; Plasterer, H. L.; Rusche, J. R.; Gottesfeld, J. M. Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol. Biol. 2011, 793, 495-508.
56. Duncan, H. F.; Smith, A. J.; Fleming, G. J.; Cooper, P. R. HDACi: Cellular Effects, Opportunities for Restorative Dentistry. J. Dent. Res. 2011.
57. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell Biochem. 1982, 42 (2), 65-82.
58. Riggs, M. G.; Whittaker, R. G.; Neumann, J. R.; Ingram, V. M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977, 268 (5619), 462-464.
59. Burgess, A.; Ruefli, A.; Beamish, H.; Warrener, R.; Saunders, N.; Johnstone, R.; Gabrielli, B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004, 23 (40), 6693-6701.
60. Chen, P. C.; Patil, V.; Guerrant, W.; Green, P.; Oyelere, A. K. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg. Med. Chem. 2008, 16 (9), 4839-4853.
61. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 2003, 46 (24), 5097-5116.
62. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25 (1), 84-90.
63. Tan, J.; Cang, S.; Ma, Y.; Petrillo, R. L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 2010, 3, 5.
64. Martinet, N.; Bertrand, P. Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag. Res. 2011, 3, 117-141.
65. Balasubramanian, S.; Verner, E.; Buggy, J. J. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett. 2009, 280 (2), 211-221.
66. Vrana, J. A.; Decker, R. H.; Johnson, C. R.; Wang, Z.; Jarvis, W. D.; Richon, V. M.; Ehinger, M.; Fisher, P. B.; Grant, S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999, 18 (50), 7016-7025.
67. Khan, A. N.; Tomasi, T. B. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol. Res. 2008, 40 (2), 164-178.
68. Mandl-Weber, S.; Meinel, F. G.; Jankowsky, R.; Oduncu, F.; Schmidmaier, R.; Baumann, P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br. J. Haematol. 2010, 149 (4), 518-528.
69. Lee, J. H.; Choy, M. L.; Ngo, L.; Foster, S. S.; Marks, P. A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (33), 14639-14644.
70. Sigalotti, L.; Fratta, E.; Coral, S.; Cortini, E.; Covre, A.; Nicolay, H. J.; Anzalone, L.; Pezzani, L.; Di Giacomo, A. M.; Fonsatti, E.; Colizzi, F.; Altomonte, M.; Calabro, L.; Maio, M. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J. Cell. Physiol. 2007, 212 (2), 330-344.
71. LaBonte, M. J.; Wilson, P. M.; Fazzone, W.; Russell, J.; Louie, S. G.; El-Khoueiry, A.; Lenz, H. J.; Ladner, R. D. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011, 71 (10), 3635-3648.
72. Lai, C. J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D. G.; Yin, L.; Samson, M.; Forrester, J.; Zifcak, B.; Xu, G. X.; DellaRocca, S.; Zhai, H. X.; Cai, X.; Munger, W. E.; Keegan, M.; Pepicelli, C. V.; Qian, C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010, 70 (9), 3647-3656.
73. Munshi, A.; Tanaka, T.; Hobbs, M. L.; Tucker, S. L.; Richon, V. M.; Meyn, R. E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer. Ther. 2006, 5 (8), 1967-1974.
74. Stimson, L.; La Thangue, N. B. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett. 2009, 280 (2), 177-183.
75. Weichert, W.; Boehm, M.; Gekeler, V.; Bahra, M.; Langrehr, J.; Neuhaus, P.; Denkert, C.; Imre, G.; Weller, C.; Hofmann, H. P.; Niesporek, S.; Jacob, J.; Dietel, M.; Scheidereit, C.; Kristiansen, G. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br. J. Cancer 2007, 97 (4), 523-530.
76. Arts, J.; Angibaud, P.; Marien, A.; Floren, W.; Janssens, B.; King, P.; van Dun, J.; Janssen, L.; Geerts, T.; Tuman, R. W.; Johnson, D. L.; Andries, L.; Jung, M.; Janicot, M.; van Emelen, K. R306465 is a novel potent inhibitor of class I histone deacetylases with broadspectrum antitumoral activity against solid and haematological malignancies. Br. J. Cancer 2007, 97 (10), 1344-1353.
77. Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108 (2), 153-164.
78. Ma, X.; Ezzeldin, H. H.; Diasio, R. B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69 (14), 1911-1934.
79. Ungerstedt, J. S.; Sowa, Y.; Xu, W. S.; Shao, Y.; Dokmanovic, M.; Perez, G.; Ngo, L.; Holmgren, A.; Jiang, X.; Marks, P. A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (3), 673-678.
80. Leibowitz, B.; Yu, J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol. Ther. 2010, 9 (6), 417-422.
81. Adams, J. M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26 (9), 1324-1337.
82. Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell. Biol. 2008, 9 (1), 47-59.
83. Ruefli, A. A.; Ausserlechner, M. J.; Bernhard, D.; Sutton, V. R.; Tainton, K. M.; Kofler, R.; Smyth, M. J.; Johnstone, R. W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (19), 10833-10838.
84. Zhao, Y.; Tan, J.; Zhuang, L.; Jiang, X.; Liu, E. T.; Yu, Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (44), 16090-16095.
85. Peart, M. J.; Tainton, K. M.; Ruefli, A. A.; Dear, A. E.; Sedelies, K. A.; O'Reilly, L. A.; Waterhouse, N. J.; Trapani, J. A.; Johnstone, R. W. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003, 63 (15), 4460-4471.
86. Emanuele, S.; Lauricella, M.; Carlisi, D.; Vassallo, B.; D'Anneo, A.; Di Fazio, P.; Vento, R.; Tesoriere, G. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007, 12 (7), 1327-1338.
87. Fandy, T. E.; Shankar, S.; Ross, D. D.; Sausville, E.; Srivastava, R. K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7 (7), 646-657.
88. Nakata, S.; Yoshida, T.; Horinaka, M.; Shiraishi, T.; Wakada, M.; Sakai, T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004, 23 (37), 6261-6271.
89. Nebbioso, A.; Clarke, N.; Voltz, E.; Germain, E.; Ambrosino, C.; Bontempo, P.; Alvarez, R.; Schiavone, E. M.; Ferrara, F.; Bresciani, F.; Weisz, A.; de Lera, A. R.; Gronemeyer, H.; Altucci, L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11 (1), 77-84.
90. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6 (1), 38-51.
91. Insinga, A.; Monestiroli, S.; Ronzoni, S.; Gelmetti, V.; Marchesi, F.; Viale, A.; Altucci, L.; Nervi, C.; Minucci, S.; Pelicci, P. G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 2005, 11 (1), 71-76.
92. Chen, C. S.; Weng, S. C.; Tseng, P. H.; Lin, H. P. Histone acetylationindependent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 2005, 280 (46), 38879-38887.
93. Kim, M. S.; Kwon, H. J.; Lee, Y. M.; Baek, J. H.; Jang, J. E.; Lee, S. W.; Moon, E. J.; Kim, H. S.; Lee, S. K.; Chung, H. Y.; Kim, C. W.; Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001, 7 (4), 437-443.
94. Deroanne, C. F.; Bonjean, K.; Servotte, S.; Devy, L.; Colige, A.; Clausse, N.; Blacher, S.; Verdin, E.; Foidart, J. M.; Nusgens, B. V.; Castronovo, V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002, 21 (3), 427-436.
95. Rossig, L.; Li, H.; Fisslthaler, B.; Urbich, C.; Fleming, I.; Forstermann, U.; Zeiher, A. M.; Dimmeler, S. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 2002, 91 (9), 837-844.
96. Jeong, J. W.; Bae, M. K.; Ahn, M. Y.; Kim, S. H.; Sohn, T. K.; Bae, M. H.; Yoo, M. A.; Song, E. J.; Lee, K. J.; Kim, K. W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111 (5), 709-720.
97. Qian, D. Z.; Kato, Y.; Shabbeer, S.; Wei, Y.; Verheul, H. M.; Salumbides, B.; Sanni, T.; Atadja, P.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 2006, 12 (2), 634-642.
98. Reddy, P.; Maeda, Y.; Hotary, K.; Liu, C.; Reznikov, L. L.; Dinarello, C. A.; Ferrara, J. L. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (11), 3921-3926.
99. Yuan, Z. L.; Guan, Y. J.; Chatterjee, D.; Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307 (5707), 269-273.
100. Ghizzoni, M.; Haisma, H. J.; Maarsingh, H.; Dekker, F. J. Histone acetyltransferases are crucial regulators in NF-kappaB mediated inflammation. Drug Discov. Today 2011, 16 (11-12), 504-511.
101. Yin, L.; Laevsky, G.; Giardina, C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J. Biol. Chem. 2001, 276 (48), 44641-44646.
102. Kaler, P.; Sasazuki, T.; Shirasawa, S.; Augenlicht, L.; Klampfer, L. HDAC2 deficiency sensitizes colon cancer cells to TNFalphainduced apoptosis through inhibition of NF-kappaB activity. Exp. Cell Res. 2008, 314 (7), 1507-1518.
103. Mayo, M. W.; Denlinger, C. E.; Broad, R. M.; Yeung, F.; Reilly, E. T.; Shi, Y.; Jones, D. R. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J. Biol. Chem. 2003, 278 (21), 18980-18989.
104. Ashburner, B. P.; Westerheide, S. D.; Baldwin, A. S., Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 2001, 21 (20), 7065-7077.
105. Law, A. Y.; Lai, K. P.; Lui, W. C.; Wan, H. T.; Wong, C. K. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation. Exp. Cell. Res. 2008, 314 (16), 2975-2984.
106. Yao, J.; Duan, L.; Fan, M.; Wu, X. NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. Pharmacol. Res. 2006, 54 (6), 406-413.
107. Abramova, M. V.; Zatulovskiy, E. A.; Svetlikova, S. B.; Pospelov, V. A. HDAC inhibitor-induced activation of NF-kappaB prevents apoptotic response of E1A+Ras-transformed cells to proapoptotic stimuli. Int. J. Biochem. Cell Biol. 2010, 42 (11), 1847-1855.
108. Schneider, G.; Kramer, O. H.; Fritsche, P.; Schuler, S.; Schmid, R. M.; Saur, D. Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J. Cell. Mol. Med. 2010, 14 (6A), 1255-1263.
109. Lehmann, A.; Denkert, C.; Budczies, J.; Buckendahl, A. C.; Darb-Esfahani, S.; Noske, A.; Muller, B. M.; Bahra, M.; Neuhaus, P.; Dietel, M.; Kristiansen, G.; Weichert, W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9, 395.
110. van Essen, D.; Engist, B.; Natoli, G.; Saccani, S. Two modes of transcriptional activation at native promoters by NF-kappaB p65. PLoS Biol. 2009, 7 (3), e73.
111. Zhou, W.; Liang, I. C.; Yee, N. S. Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer. Cancer Biol. Ther. 2011, 11 (7), 659-670.
112. Miyake, K.; Yoshizumi, T.; Imura, S.; Sugimoto, K.; Batmunkh, E.; Kanemura, H.; Morine, Y.; Shimada, M. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008, 36 (3), e1-e9.
113. Fritsche, P.; Seidler, B.; Schuler, S.; Schnieke, A.; Gottlicher, M.; Schmid, R. M.; Saur, D.; Schneider, G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009, 58 (10), 1399-1409.
114. Schuler, S.; Fritsche, P.; Diersch, S.; Arlt, A.; Schmid, R. M.; Saur, D.; Schneider, G. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol. Cancer 2010, 9, 80.
115. Marshall, G. M.; Gherardi, S.; Xu, N.; Neiron, Z.; Trahair, T.; Scarlett, C. J.; Chang, D. K.; Liu, P. Y.; Jankowski, K.; Iraci, N.; Haber, M.; Norris, M. D.; Keating, J.; Sekyere, E.; Jonquieres, G.; Stossi, F.; Katzenellenbogen, B. S.; Biankin, A. V.; Perini, G.; Liu, T. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 2010, 29 (44), 5957-5968.
116. Ouaissi, M.; Sielezneff, I.; Silvestre, R.; Sastre, B.; Bernard, J. P.; Lafontaine, J. S.; Payan, M. J.; Dahan, L.; Pirro, N.; Seitz, J. F.; Mas, E.; Lombardo, D.; Ouaissi, A. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann. Surg. Oncol. 2008, 15 (8), 2318-2328.
117. Dokmanovic, M.; Perez, G.; Xu, W.; Ngo, L.; Clarke, C.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther. 2007, 6 (9), 2525-2534.
118. Moore, B. S.; Eustaquio, A. S.; McGlinchey, R. P. Advances in and applications of proteasome inhibitors. Curr. Opin. Chem. Biol. 2008, 12 (4), 434-440.
119. Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A. K.; Simms-Waldrip, T.; Fu, C.; Sakamoto, K. M. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res. 2008, 68 (8), 2557-2560.
120. Wu, W. K.; Cho, C. H.; Lee, C. W.; Wu, K.; Fan, D.; Yu, J.; Sung, J. J. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 2010, 293 (1), 15-22.
121. Aldana-Masangkay, G. I.; Sakamoto, K. M. The role of HDAC6 in cancer. J. Biomed. Biotechnol. 2011, 2011, 875824.
122. Kozikowski, A. P.; Chen, Y.; Gaysin, A. M.; Savoy, D. N.; Billadeau, D. D.; Kim, K. H. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem 2008, 3 (3), 487-501.
123. Frankland-Searby, S.; Bhaumik, S. R. The 26S proteasome complex: An attractive target for cancer therapy. Biochim. Biophys. Acta 2012, 1825 (1), 64-76.
124. Krantz, S. B.; Shields, M. A.; Dangi-Garimella, S.; Munshi, H. G.; Bentrem, D. J. Contribution of Epithelial-to-Mesenchymal Transition and Cancer Stem Cells to Pancreatic Cancer Progression. J. Surg. Res. 2011.
125. Yang, J.; Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14 (6), 818-829.
126. Pignatelli, M.; Ansari, T. W.; Gunter, P.; Liu, D.; Hirano, S.; Takeichi, M.; Kloppel, G.; Lemoine, N. R. Loss of membranous Ecadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J. Pathol. 1994, 174 (4), 243-248.
127. Aghdassi, A.; Sendler, M.; Guenther, A.; Mayerle, J.; Behn, C. O.; Heidecke, C. D.; Friess, H.; Buchler, M.; Evert, M.; Lerch, M. M.; Weiss, F. U. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates Ecadherin expression in pancreatic cancer. Gut 2011.
128. von Burstin, J.; Eser, S.; Paul, M. C.; Seidler, B.; Brandl, M.; Messer, M.; von Werder, A.; Schmidt, A.; Mages, J.; Pagel, P.; Schnieke, A.; Schmid, R. M.; Schneider, G.; Saur, D. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009, 137 (1), 361-371.
129. Hamacher, R.; Schmid, R. M.; Saur, D.; Schneider, G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol. Cancer 2008, 7, 64.
130. Flis, S.; Gnyszka, A.; Flis, K.; Splawinski, J. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. Eur. J. Pharmacol. 2010, 627 (1-3), 26-32.
131. Song, K.; Li, Q.; Jiang, Z. Z.; Guo, C. W.; Li, P. Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelialmesenchymal transition inducer in pancreatic cancer. Cancer Biol. Ther. 2011, 12 (5), 388-398.
132. Garcia-Morales, P.; Gomez-Martinez, A.; Carrato, A.; Martinez- Lacaci, I.; Barbera, V. M.; Soto, J. L.; Carrasco-Garcia, E.; Menendez-Gutierrez, M. P.; Castro-Galache, M. D.; Ferragut, J. A.; Saceda, M. Histone deacetylase inhibitors induced caspaseindependent apoptosis in human pancreatic adenocarcinoma cell lines. Mol. Cancer Ther. 2005, 4 (8), 1222-1230.
133. Sato, N.; Ohta, T.; Kitagawa, H.; Kayahara, M.; Ninomiya, I.; Fushida, S.; Fujimura, T.; Nishimura, G.; Shimizu, K.; Miwa, K. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int. J. Oncol. 2004, 24 (3), 679-685.
134. El Maalouf, G.; Le Tourneau, C.; Batty, G. N.; Faivre, S.; Raymond, E. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat. Rev. 2009, 35 (2), 167-174.
135. Donadelli, M.; Costanzo, C.; Beghelli, S.; Scupoli, M. T.; Dandrea, M.; Bonora, A.; Piacentini, P.; Budillon, A.; Caraglia, M.; Scarpa, A.; Palmieri, M. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim. Biophys. Acta 2007, 1773 (7), 1095-1106.
136. Bai, J.; Demirjian, A.; Sui, J.; Marasco, W.; Callery, M. P. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS- 341 synergistically induce apoptosis in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2006, 348 (4), 1245-1253.
137. Iwahashi, S.; Shimada, M.; Utsunomiya, T.; Morine, Y.; Imura, S.; Ikemoto, T.; Mori, H.; Hanaoka, J.; Sugimoto, K.; Saito, Y. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-alpha on pancreatic cancer cells. Int. J. Clin. Oncol. 2011.
138. Sung, V.; Richard, N.; Brady, H.; Maier, A.; Kelter, G.; Heise, C. Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. Cancer Sci. 2011, 102 (6), 1201-1207.
139. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348 (26), 2609-2617.
140. Lee, J. K.; Ryu, J. K.; Yang, K. Y.; Woo, S. M.; Park, J. K.; Yoon, W. J.; Lee, S. H.; Jeong, K. S.; Kim, Y. T.; Yoon, Y. B. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. Pancreas 2011, 40 (6), 966-973.
141. Iwahashi, S.; Ishibashi, H.; Utsunomiya, T.; Morine, Y.; Ochir, T. L.; Hanaoka, J.; Mori, H.; Ikemoto, T.; Imura, S.; Shimada, M. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J. Med. Invest. 2011, 58 (1-2), 106-109.
142. Monks, A.; Hose, C. D.; Pezzoli, P.; Kondapaka, S.; Vansant, G.; Petersen, K. D.; Sehested, M.; Monforte, J.; Shoemaker, R. H. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs 2009, 20 (8), 682-692.
143. Spratlin, J. L.; Pitts, T. M.; Kulikowski, G. N.; Morelli, M. P.; Tentler, J. J.; Serkova, N. J.; Eckhardt, S. G. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 2011, 31 (4), 1093-1103.
144. Nawrocki, S. T.; Carew, J. S.; Pino, M. S.; Highshaw, R. A.; Andtbacka, R. H.; Dunner, K., Jr.; Pal, A.; Bornmann, W. G.; Chiao, P. J.; Huang, P.; Xiong, H.; Abbruzzese, J. L.; McConkey, D. J. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006, 66 (7), 3773-3781.
145. Schemies, J.; Sippl, W.; Jung, M. Histone deacetylase inhibitors that target tubulin. Cancer Lett. 2009, 280 (2), 222-232.
146. Zhu, Q. Y.; Wang, Z.; Ji, C.; Cheng, L.; Yang, Y. L.; Ren, J.; Jin, Y. H.; Wang, Q. J.; Gu, X. J.; Bi, Z. G.; Hu, G.; Yang, Y. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011, 2, e117.
147. Fujisawa, T.; Joshi, B. H.; Puri, R. K. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. J. Transl. Med. 2011, 9, 37.
148. Fujiwara, Y.; Yamamoto, N.; Yamada, Y.; Yamada, K.; Otsuki, T.; Kanazu, S.; Iwasa, T.; Hardwick, J. S.; Tamura, T. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci. 2009, 100 (9), 1728-1734.
149. Debinski, W.; Obiri, N. I.; Powers, S. K.; Pastan, I.; Puri, R. K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res. 1995, 1 (11), 1253-1258.
150. Bots, M.; Johnstone, R. W. Rational combinations using HDAC inhibitors. Clin. Cancer Res. 2009, 15 (12), 3970-3977.
151. Richards, D. A.; Boehm, K. A.; Waterhouse, D. M.; Wagener, D. J.; Krishnamurthi, S. S.; Rosemurgy, A.; Grove, W.; Macdonald, K.; Gulyas, S.; Clark, M.; Dasse, K. D. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann. Oncol. 2006, 17 (7), 1096-1102.
152. Hurwitz, H.; Nelson, B.; O'Dwyer, P. J.; Chiorean, E. G.; Gabrail, N.; Laille, E.; Drouin, M.; Rothenberg, M. L.; Chan, E. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. J. Clin. Oncol. 2008, 26 (15S-May 20).
153. Doss, H. H.; Jones, S. F.; Infante, J. R.; Spigel, D. R.; Willcutt, N.; Lamar, R.; Barton, J.; Keegan, M.; Burris, H. A. A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J. Clin. Oncol. 2008, 26 (15S-May 20).
154. Jones, S. F.; Bendell, J. C.; Infante, J. R.; Spigel, D. R.; Thompson, D. S.; Yardley, D. A.; Greco, F. A.; Murphy, P. B.; Burris, H. A., 3rd. A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors. Clin. Adv. Hematol. Oncol. 2011, 9 (3), 225-230.
155. U.S. National Institutes of Health. Health Information: Clinical Trials. http://www.clinicaltrials.gov/ct2/show/NCT00831493. (Accessed November 30, 2011).
156. U.S. National Institutes of Health. Health Information: Clinical Trials. http://www.clinicaltrials.gov/ct2/show/NCT00983268. (Accessed November 30, 2011).
157. U.S. National Institutes of Health. Health Information: Clinical Trials. http://www.clinicaltrials.gov/ct2/show/NCT00948688. (Accessed November 30, 2011).
158. U.S. National Institutes of Health. Health Information: Clinical Trials. http://www.clinicaltrials.gov/ct2/show/NCT00667082. (Accessed November 30, 2011).
159. U.S. National Institutes of Health. Health Information: Clinical Trials. http://www.clinicaltrials.gov/ct2/show/NCT01333631. (Accessed November 30, 2011).
160. Wang, Z.; Li, Y.; Ahmad, A.; Banerjee, S.; Azmi, A. S.; Kong, D.; Sarkar, F. H. Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. Gastroenterol. Hepatol. 2011, 8 (1), 27-33.
161. Vaccaro, V.; Melisi, D.; Bria, E.; Cuppone, F.; Ciuffreda, L.; Pino, M. S.; Gelibter, A.; Tortora, G.; Cognetti, F.; Milella, M. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin. Ther. Targets 2011, 15 (10), 1183-1196.
162. Strimpakos, A. S.; Syrigos, K. N.; Saif, M. W. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver 2010, 4 (4), 433-449.
163. Kaminskyy, V. O.; Surova, O. V.; Vaculova, A.; Zhivotovsky, B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011.